cbdMD, Inc. Stock

YCBD

US12482W4087

Pharmaceuticals

Delayed NYSE 03:42:58 07/11/2026 HKT			5-day change	1st Jan Change
0.4099 ^USD	+5.64%		+7.11%	-69.64%

11-02	CbdMD, Inc. completed the acquisition of Operating assets and brands of Twinlab Consolidation Corporation.	CI
09-03	CbdMD, Inc. entered into a definitive asset purchase agreement to acquire Operating assets and brands of Twinlab Consolidation Corporation for $2.9 million.	CI

Last Transcript: cbdMD, Inc.

CbdMD, Inc., Q3 2026 Earnings Call, Aug 13, 2026

08-14

More transcripts

Analysts' recommendations: cbdMD, Inc.

08-17	Maxim Group Downgrades cbdMD to Hold From Buy	MT
05/10/23	Maxim Starts Coverage on cbdMD with Buy Rating, $3 Price Target	MT
18/06/21	CbdMD : Cantor Fitzgerald Adjusts Price Target for cbdMD to $3.25 from $4.10, Maintains Neutral Rating	MT

More recommendations

Managers and Directors: cbdMD, Inc.

Manager	Title	Age	Since
T. Kennedy CEO	Chief Executive Officer	47	01/03/2023
Zeb Booker CTO	Chief Tech/Sci/R&D Officer	-	01/01/2019
Sibyl Swift CTO	Chief Tech/Sci/R&D Officer	45	-

Director	Title	Age	Since
Bakari Sellers BRD	Director/Board Member	41	01/03/2017
William Raines BRD	Director/Board Member	66	19/04/2019
Scott Stephen CHM	Chairman	60	03/06/2022

More insiders

cbdMD, Inc. is a consumer wellness company focused on the development, manufacturing, marketing, and sale of supplement brands powered by natural compounds. Its hemp-derived cannabinoids, include full-spectrum cannabidiol (CBD) formulations, hemp-derived Delta-9 THC products and a range of functional products designed to address key wellness needs, such as sleep, recovery, mood, discomfort, mobility, cognitive function, and stress management. It operates a multi-brand portfolio anchored by its flagship cbdMD line, which offers oils, gummies, capsules, soft-gels, topicals, functional formulations, and hemp-derived compliant Delta-9 THC products. Its Paw CBD pet-wellness brand provides tinctures, chews, and topicals for dogs and cats. Its ATRX platform offers non-cannabinoid functional ingredients such as functional mushrooms. Its Herbal Oasis (Oasis) brand is a premium hemp-derived THC-infused social seltzer that blends cannabinoids and nootropic mushrooms.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/11/26	US$0.4099	+5.64%	49,472
05/11/26	US$0.3880	-4.43%	65,075
04/11/26	US$0.4060	-3.10%	170,369
03/11/26	US$0.4190	+5.62%	273,835
02/11/26	US$0.3967	+3.66%	298,490

Delayed Quote NYSE

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.3880

Average target price

Consensus

EPS Estimates

Evolution of Analysts' Estimates - EPS - cbdMD, Inc.

Revisions to estimates

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - cbdMD, Inc.

Company calendar

Market Cap	4.35M 3.9M 3.56M 3.25M 6.13M 409M 6.32M 42.95M 17.13M 218M 16.32M 15.97M 688M	P/E 2026 *	-1.18x	P/E 2027 *	-2.04x
Enterprise Value	4.35M 3.9M 3.56M 3.25M 6.13M 409M 6.32M 42.95M 17.13M 218M 16.32M 15.97M 688M	EV / Sales 2026 *	0.2x	EV / Sales 2027 *	0.15x
Free-Float	90%	Yield 2026 *	-	Yield 2027 *	-

09-24	Reserveage Launches Longev+ Exclusively at The Vitamin Shoppe, Bringing Strength Into the Healthy Aging Conversation	PR
09-02	CbdMD Enters Definitive Agreement to Acquire Twinlab Brands, Expanding Into Legacy Supplements, Sports Nutrition, Women's Beauty, Weight Loss and Longevity Wellness	PR
08-14	CbdMD Reports 20% Year-over-Year Revenue Growth for the Third Fiscal Quarter of 2026	PR
08-11	CbdMD, Inc. to Host Conference Call to Discuss June 30, 2026, Third Quarter Results	PR
08-03	CbdMD Applauds Proposed SENATE SPENDING BILL That Would Protect Access to Full-Spectrum CBD and Other Naturally Derived Hemp Products	PR

1 day	+5.64%
1 week	+7.11%
Current month	+7.11%
1 month	+0.47%
3 months	-27.54%
6 months	-55.08%
Current year	-69.64%

1 week	0.37	0.46
1 month	0.33	0.46
Current year	0.33	1.34
1 year	0.33	2.56
3 years	0.33	13.84
5 years	0.33	727.2
10 years	0.33	2,606.4

Date	Insider	Type	Main position	Quantity	% Market Cap.
14/4/26	Jeffrey Porter	Free	Director	1,572	0.0150%
14/4/26	William Raines	Free	Director	1,572	0.0150%
14/4/26	Bakari Sellers	Free	Director	1,572	0.0150%

cbdMD, Inc. Stock

Stocks

YCBD

US12482W4087

Pharmaceuticals

Valuation: cbdMD, Inc.

Chart: cbdMD, Inc.

Latest news: cbdMD, Inc.

Last Transcript: cbdMD, Inc.

Analysts' recommendations: cbdMD, Inc.

Press Releases: cbdMD, Inc.

Quotes and Performance

Price Extremes

Managers and Directors: cbdMD, Inc.

Latest insider transactions

Other Pharmaceuticals

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CBDMD, INC.	+5.64%	+7.11%	-47.45%	-92.78%	4.35M
ELI LILLY AND COMPANY	-0.23%	-3.96%	+45.23%	+128.75%	1,216B
JOHNSON & JOHNSON	+1.07%	+0.82%	+47.32%	+81.57%	656B
ABBVIE INC.	+0.46%	-1.57%	+32.52%	+105.57%	509B
ROCHE HOLDING AG	-0.36%	-3.25%	+47.17%	+64.58%	384B
MERCK & CO., INC.	-0.21%	-1.91%	+70.98%	+40.56%	362B
NOVARTIS AG	-0.78%	-0.52%	+30.57%	+57.98%	311B
ASTRAZENECA PLC	-0.80%	-0.21%	+8.54%	+35.56%	293B
AMGEN INC.	+0.12%	-0.92%	+46.31%	+69.24%	249B
GILEAD SCIENCES, INC.	+0.01%	-1.66%	+36.02%	+106.86%	208B
Average	+0.42%	+0.54%	+31.72%	+59.79%	418.78B
Weighted average by Cap.	-0.05%	+0.03%	+42.37%	+88.63%

	2026 *	2027 *
Net sales	21.92M 19.66M 17.97M 16.4M 30.91M 2.06B 31.88M 217M 86.37M 1.1B 82.29M 80.52M 3.47B	28.6M 25.65M 23.44M 21.4M 40.31M 2.69B 41.58M 283M 113M 1.43B 107M 105M 4.53B
Net income	-3.33M -2.99M -2.73M -2.49M -4.7M -313M -4.85M -32.92M -13.13M -167M -12.51M -12.24M -528M	-4.95M -4.44M -4.05M -3.7M -6.97M -465M -7.19M -48.87M -19.49M -248M -18.56M -18.17M -783M
Net Debt	-	-

Markets		Quality
NYSE	YCBD	Delayed
CBOE	YCBD	Real-time